Dmitry Samarsky, Ph.D.Chief Technology Officer at Sirnaomics
Dr. Samarsky has been at the inception of the RNAi technology and drug discovery, starting in 2001 as Director of Technology Development at Sequitur (later acquired by Invitrogen), followed by Director of Technology Development role at Dharmacon (now part of GE). He then served as VP of Technology Development at RXi Pharmaceuticals, SVP of Technology and International Business Development at RiboBio, and, most recently, Chief Scientific Officer at Silence Therapeutics. Dr. Samarsky authored 40+ scientific papers, articles, book chapters, patents and patent applications, and was an invited speaker, panelist and chairman at 100+ international conferences. Dr. Samarsky received his PhD in biochemistry and molecular biology from University of Massachusetts, Amherst (1998), followed by postdoctoral position as H. Arthur Smith Fellow for Cancer Research in laboratory of Dr. Michael Green at University of Massachusetts Medical School.